var data={"title":"Lacosamide: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Lacosamide: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/369090?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=lacosamide-drug-information\" class=\"drug drug_general\">see &quot;Lacosamide: Drug information&quot;</a> and <a href=\"topic.htm?path=lacosamide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Lacosamide: Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6786825\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Vimpat</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11508103\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Vimpat</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9406528\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Anticonvulsant, Miscellaneous</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9406539\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=lacosamide-drug-information\" class=\"drug drug_general\">see &quot;Lacosamide: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Seizure, partial onset:</b> <b>Note:</b> For patients already on a single antiepileptic and converting to lacosamide monotherapy, maintain the maintenance dose for 3 days before beginning withdrawal of the concomitant antiepileptic drug. Gradually taper the concomitant antiepileptic drug over &ge;6 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;4 to 17 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Monotherapy and adjunctive therapy</i>:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">11 to &lt;30 kg: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Initial: 1 mg/kg/dose twice daily; may be increased at weekly intervals by 1 mg/kg/dose twice daily based on response and tolerability</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Maintenance: 3 to 6 mg/kg/dose twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">30 to &lt;50 kg: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Initial: 1 mg/kg/dose twice daily; may be increased at weekly intervals by 1 mg/kg/dose twice daily based on response and tolerability</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Maintenance: 2 to 4 mg/kg/dose twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;50 kg: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Initial (monotherapy and adjunctive therapy): 50 mg twice daily; may be increased at weekly intervals of 50 mg twice daily based on response and tolerability</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Maintenance:</p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">\n      <i>Monotherapy:</i> 150 to 200 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">\n      <i>Adjunctive therapy</i>: 100 to 200 mg twice daily. <b>Note: </b>In adjunctive clinical trials in adults, doses higher than 400 mg/day were not more effective and were associated with more adverse reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;17 years: <b>Note:</b> When switching from oral to IV formulations, the total daily dose and frequency should be the same; IV therapy should only be used temporarily. Clinical study experience of IV lacosamide is limited to 5 days of consecutive treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Monotherapy:</i> Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Initial: 100 mg twice daily; may be increased at weekly intervals by 50 mg twice daily based on response and tolerability</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Alternate initial dosage: Loading dose: 200 mg followed approximately 12 hours later by 100 mg twice daily for 1 week; may be increased at weekly intervals by 50 mg twice daily based on response and tolerability. <b>Note:</b> Administer loading doses under medical supervision because of the increased incidence of CNS adverse reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Maintenance: 150 to 200 mg twice daily. <b>Note: </b>In adjunctive clinical trials in adults, doses higher than 400 mg/day were not more effective and were associated with more adverse reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Adjunctive therapy:</i> Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Initial: 50 mg twice daily; may be increased at weekly intervals by 50 mg twice daily based on response and tolerability</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Alternative initial dosage: Loading dose of 200 mg followed approximately 12 hours later by 100 mg twice daily for 1 week; may be increased at weekly intervals by 50 mg twice daily based on response and tolerability. <b>Note:</b> Administer loading doses under medical supervision because of the increased incidence of CNS adverse reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Maintenance dose: 100 to 200 mg twice daily.<b> Note: </b>In adjunctive clinical trials in adults, doses higher than 400 mg/day were not more effective and were associated with more adverse reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Seizure, severe; refractory:</b> Limited data available: Infants &ge;6 months, Children, and Adolescents &lt;17 years: Oral: Initial: 1 to 2 mg/kg/day divided twice daily (usual maximum initial dose: 50 mg/dose); may titrate by 1 to 2 mg/kg/day weekly to effect. Range of reported mean maintenance doses: 4.7 to 15.2 mg/kg/day. Dosing based on large prospective, open label trials, small retrospective trials and case series; reported experience is primarily as adjunctive therapy with a few pediatric patients receiving monotherapy (Casas-Fern&aacute;ndez 2012; Gavatha 2011; Grosso 2014a; Grosso 2014b; Guilhoto 2011; Heyman 2012; Kim 2014; Kliegman 2015; Rastogi 2012; Verrotti 2013; Yorns 2014). In the largest, multicenter, prospective trial of 130 pediatric patients (mean age: 8.01 &plusmn; 4.25 years; range: 6 months to 16 years) with refractory focal seizures, therapy was initiated at 1 to 2 mg/kg/day divided twice daily and titrated by 1 or 2 mg/kg/day increments to effect; mean reported dose was 6.8 &plusmn; 2.39 mg/kg (effective dose range: 2.14 to 14.3 mg/kg/day); after 3 months of therapy, 62.3% of patients had a &gt;50% decrease in seizure frequency, including 16.2% who became seizure free; five patients withdrew due to adverse effects. While doses as high as 20 mg/kg/day were reported in this study, this was isolated to the group of subjects that reported no decrease in seizure frequency during therapy (Casas-Fern&aacute;ndez 2012). In another large prospective trial of 59 pediatric patients (mean age: 10.8 &plusmn; 3.14 years; range: 4 to 15 years) with focal, general, or mixed seizure types, therapy was initiated at 1 mg/kg/day, titrating weekly by 1 mg/kg/day increments to a target dose of 3 to 12 mg/kg/day; after 3 months of therapy (n=59), 47.4% of patients had a &ge;50% decrease in seizure frequency, 6.8% were seizure free, 11.9% reported an increase in seizure frequency, and two patients withdrew due to adverse effects; at 6-month follow up (n=50), 52.5% had a &ge;50% decrease in seizure frequency and four patients withdrew due to lack of efficacy and at 12-month follow-up (n=46), 47.4% had a &ge;50% decrease in seizure frequency (Verrotti 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Seizure, partial onset:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Monotherapy: Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial: 100 mg twice daily; may be increased at weekly intervals by 50 mg twice daily based on response and tolerability.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternative initial dosage: Loading dose: 200 mg followed approximately 12 hours later by 100 mg twice daily for 1 week; may be increased at weekly intervals by 50 mg twice daily based on response and tolerability. <b>Note:</b> Administer loading doses under medical supervision because of the increased incidence of CNS adverse reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance: 150 to 200 mg twice daily. <b>Note:</b> For patients already on a single antiepileptic and converting to lacosamide monotherapy, maintain the maintenance dose for 3 days before beginning withdrawal of the concomitant antiepileptic drug. Gradually taper the concomitant antiepileptic drug over &ge;6 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adjunctive therapy: Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial: 50 mg twice daily; may be increased at weekly intervals by 50 mg twice daily based on response and tolerability.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternative initial dosage: Loading dose of 200 mg followed approximately 12 hours later by 100 mg twice daily for 1 week; may be increased at weekly intervals by 50 mg twice daily based on response and tolerability. <b>Note:</b> Administer loading doses under medical supervision because of the increased incidence of CNS adverse reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance dose: 100 to 200 mg twice daily. <b>Note: </b>In adjunctive clinical trials, doses higher than 400 mg/day were not more effective and were associated with more adverse reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Switching from oral to IV dosing:</b> When switching from oral to IV formulations, the total daily dose and frequency should be the same; IV therapy should only be used temporarily. Clinical study experience of IV lacosamide is limited to 5 days of consecutive treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Children &ge;4 years, Adolescents, and Adults: Titrate dose with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate renal impairment: No dose adjustment necessary; however, in patients with renal impairment taking concomitant strong CYP3A4 and/or CYP2C9 inhibitors, dosage reduction may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe renal impairment (CrCl &le;30 mL/minute): Maximum daily dose: Reduce dose to 75% of maximum dose. Further dosage reduction/limitation may be necessary with concomitant use of strong CYP3A4 and/or CYP2C9 inhibitors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">End-stage renal disease (ESRD) requiring hemodialysis: Maximum daily dose: Reduce dose to 75% of maximum dose. Further dosage reduction/limitation may be necessary with concomitant use of strong CYP3A4 and/or CYP2C9 inhibitors. Removed by hemodialysis; after 4-hour HD treatment, a supplemental dose of up to 50% should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Children &ge;4 years, Adolescents, and Adults: Titrate dose with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate hepatic impairment: Maximum daily dose: Reduce dose to 75% of maximum dose. Further dosage reduction/limitation may be necessary in patients taking concomitant strong CYP3A4 and/or CYP2C9 inhibitors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe hepatic impairment: Use is not recommended</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6790656\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vimpat: 200 mg/20 mL (20 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vimpat: 10 mg/mL (200 mL, 465 mL) [contains aspartame, methylparaben, polyethylene glycol, propylene glycol; strawberry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vimpat: 50 mg [contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vimpat: 100 mg, 150 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vimpat: 200 mg [contains fd&amp;c blue #2 aluminum lake]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6790309\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9590984\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-V</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874836\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lacosamide oral solution: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM501649.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn//CovC0x0ey2BbNY46aAsKLNKMvdeCu1QgL5cO3HZH/Ng==&amp;TOPIC_ID=83877\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM501649.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lacosamide tablets: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM501645.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn//CovC0x0ey2BbNY46aAsKLt+x8TW0ecX/BRt39f3UH2w==&amp;TOPIC_ID=83877\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM501645.pdf</a> and <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM501648.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn//CovC0x0ey2BbNY46aAsKLySUDohv8H/OFwCp4wrrM4Q==&amp;TOPIC_ID=83877\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM501648.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vimpat: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022253s039,022254s030,022255s022lbl.pdf#page=20&amp;token=dCzmWjbeJOsD7mQjC+Slo9ppmkOL3xJqFJfSpvf3zsR9YyvaPIdc0pv7dr0nDtWJJoOFBSBY/Ty0mLcCrzWUc9ZJJXofuw3w42K2TXbUptfb9wiMEcS2KcH/I/FSO6yX&amp;TOPIC_ID=83877\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022253s039,022254s030,022255s022lbl.pdf#page=20</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9406540\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Solution, tablets: May be administered with or without food. Oral solution should be administered with a calibrated measuring device (not a household teaspoon or tablespoon). May be administered via a nasogastric or gastrostomy tube.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Administer over 30 to 60 minutes; if necessary may infuse over 15 minutes, but higher incidence of CNS adverse effects (eg, dizziness, somnolence, paresthesia) may occur; monitor closely. May be administered undiluted or may be further diluted with a compatible diluent.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6790525\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions are permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F). Do not freeze. Stable when mixed with compatible diluents (NS, LR, D5W) for up to 4 hours at room temperature. Discard any unused portion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral solution, tablets: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions are permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F). Do not freeze oral solution. Discard any unused portion of oral solution after 7 weeks.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9406529\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Solution, tablets: Adjunctive or monotherapy in the treatment of partial-onset seizures (FDA approved in ages &ge;4 years and adults); has also been used for the treatment of refractory seizures</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Short-term adjunctive or monotherapy in the treatment of partial-onset seizures when oral therapy is not feasible (FDA approved in ages &ge;17 years and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6790305\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lacosamide may be confused with zonisamide</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vimpat may be confused with Vimovo</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6790444\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Syncope (adults; dose-related: &gt;400 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Abnormal gait, ataxia, depression, dizziness, drowsiness, equilibrium disturbance, fatigue, headache, memory impairment, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Bruise</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum ALT</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Local irritation, pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision, diplopia, nystagmus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Laceration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abnormal hepatic function tests, acute psychosis, aggressive behavior, agitation, agranulocytosis, anemia, angioedema, atrial fibrillation, atrial flutter, atrioventricular block, bradycardia, cerebellar syndrome, cognitive dysfunction, disturbance in attention, DRESS syndrome, euphoria, falling, hallucination, hepatitis, insomnia, nephritis, neutropenia, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6790319\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling:</i> There are no contraindications listed in manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to lacosamide or any component of the formulation; second- or third-degree atrioventricular (AV) block (current or history of).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6790403\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular effects: Lacosamide may prolong PR interval; second degree and complete AV block has also been reported. Use caution in patients with conduction problems (eg, first/second degree atrioventricular block and sick sinus syndrome without pacemaker), sodium channelopathies (eg, Brugada syndrome), myocardial ischemia, heart failure, structural heart disease, or if concurrent use with other drugs that prolong the PR interval; ECG is recommended prior to initiating therapy and when at the steady state maintenance dose. Monitor closely with IV lacosamide administration; bradycardia and AV block have occurred during infusions. Instruct patients to contact their healthcare provider if signs or symptoms of conduction problems occur (eg, low or irregular pulse, feeling of lightheadedness and fainting). During short-term trials, atrial fibrillation/flutter, or syncope occurred slightly more often in patients with diabetic neuropathy and/or cardiovascular disease. In addition, in open-label studies, syncope has been associated with a history of cardiac disease risk factors and use of drugs that slow AV conduction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Dizziness and ataxia may occur during therapy; patients should be cautioned about performing tasks which require alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiorgan hypersensitivity reactions (drug reaction with eosinophilia and systemic symptoms [DRESS]): Potentially serious (sometimes fatal, possibly delayed) multiorgan hypersensitivity reactions have been reported with some antiepileptic drugs (rare); monitor for signs and symptoms of possible disparate manifestations associated with lymphatic, hepatic, renal, and/or hematologic organ systems; gradual discontinuation and conversion to alternate therapy may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ophthalmic effects: Blurred vision and diplopia may occur during therapy. Patients with persistent visual disturbances may need further assessment. Consider increased monitoring in patients with preexisting ocular conditions or vision-related issues.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify health care provider immediately if symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Not recommended for use in patients with severe hepatic impairment; dosage adjustment required for mild to moderate hepatic impairment. Further dosage adjustment may be necessary in patients with hepatic impairment taking concomitant strong CYP3A4 and/or CYP2C9 inhibitors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use caution in patients with renal impairment; dosage adjustment required for severe renal impairment (CrCl &le;30 mL/minute) and supplementation may be necessary in hemodialysis. Patients with any degree of renal impairment taking concomitant strong CYP3A4 and/or CYP2C9 inhibitors may require dosage adjustment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Phenylalanine: Some products may contain phenylalanine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually (&ge;1 week) to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26021848\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">In vitro data has shown lacosamide interferes with CRMP-2, a protein involved with neuronal differentiation and control of axonal outgrowth; potential effect on CNS development cannot be excluded. Lacosamide administered to neonatal and juvenile rats resulted in decreased brain weights and long-term neurobehavioral changes including learning and memory deficits. Studies of the effects of lacosamide on human CNS development are needed before this medication can be recommended for routine use in pediatric patients &lt;4 years of age.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299564\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C19 (minor), CYP2C9 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6802892\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=83877&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Bradycardia-Causing Agents: May enhance the AV-blocking effect of Lacosamide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May enhance the AV-blocking effect of Lacosamide. CarBAMazepine may decrease the serum concentration of Lacosamide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Strong): May increase the serum concentration of Lacosamide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Lacosamide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Delavirdine: May increase the serum concentration of Lacosamide. Management: Lacosamide prescribing information cautions that a lacosamide dose reduction may be warranted in patients with renal dysfunction or mild-moderate hepatic impairment who are also using a strong inhibitor of CYP2C9 and CYP3A4, such as delavirdine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of Lacosamide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May diminish the therapeutic effect of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiCARdipine: May increase the serum concentration of Lacosamide. Management: Lacosamide prescribing information cautions that a lacosamide dose reduction may be warranted in patients with renal dysfunction or mild-moderate hepatic impairment who are also using a strong inhibitor of CYP2C9 and CYP3A4, such as delavirdine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PHENobarbital: May decrease the serum concentration of Lacosamide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of Lacosamide.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6790315\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events were observed in animal reproduction studies. Information related to pregnancy outcomes following maternal use of lacosamide is limited (Hoeltzenbein 2011). In general, maternal polytherapy with antiepileptic drugs may increase the risk of congenital malformations; monotherapy with the lowest effective dose is recommended. Newborns of women taking antiepileptic medications may be at an increased risk of adverse events (Harden and Meader 2009).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Patients exposed to lacosamide during pregnancy are encouraged to enroll themselves into the NAAED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at http://www.aedpregnancyregistry.org.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9406541\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Seizure frequency, duration, and severity; patients with conduction problems, concomitant medications known to prolong the PR interval, or severe cardiac disease should have ECG tracing prior to start of therapy and when at steady-state; monitor heart rate and blood pressure during IV administration; monitor hepatic and renal function; suicidality (eg, suicidal thoughts, depression, behavioral changes) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6790564\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <i>In vitro</i> studies have shown that lacosamide stabilizes hyperexcitable neuronal membranes and inhibits repetitive neuronal firing by enhancing the slow inactivation of sodium channels (with no effects on fast inactivation of sodium channels). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6790566\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Completely</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: ~0.6 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &lt;15%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP3A4, CYP2C9, and CYP2C19; forms metabolite, O-desmethyl-lacosamide (inactive)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: ~100%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;4 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mean weight 11 kg: 7.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mean weight 28.9 kg: 10.6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mean weight 70 kg: 14.8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: ~13 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Oral: 1 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (95%; 40% as unchanged drug, 30% as inactive metabolite, 20% as uncharacterized metabolite); feces (&lt;0.5%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16321857\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Vimpat Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/20 mL (20 mL): $84.81</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Vimpat Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (200 mL): $401.02</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Vimpat Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (60): $620.02</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (60): $969.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (60): $1,026.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (60): $1,026.89</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961941\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aldinam (CL);</li>\n      <li>Lacasa (IN);</li>\n      <li>Lacosam (BD, IN);</li>\n      <li>Lacoset (IN);</li>\n      <li>Lacotem (AR);</li>\n      <li>Vimpat (AR, AT, AU, BB, BE, CH, CO, CR, CY, CZ, DE, DK, DO, EE, ES, FR, GB, GR, GT, HK, HN, HR, HU, IE, IL, IS, JP, KR, LB, LT, LU, MT, MY, NI, NL, NO, NZ, PA, PH, PL, PT, QA, RO, RU, SE, SI, SK, SV, TH, TR, UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Casas-Fern&aacute;ndez C, Mart&iacute;nez-Bermejo A, Rufo-Campos M, et al. Efficacy and tolerability of lacosamide in the concomitant treatment of 130 patients under 16 years of age with refractory epilepsy: a prospective, open-label, observational, multicenter study in Spain. <i>Drugs R D</i>. 2012;12(4):187-197.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/23193979 /pubmed\" target=\"_blank\" id=\"23193979 \">23193979 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gavatha M, Ioannou I, and Papavasiliou AS, &quot;Efficacy and Tolerability of Oral Lacosamide as Adjunctive Therapy in Pediatric Patients With Pharmacoresistant Focal Epilepsy,&quot; <i>Epilepsy Behav</i>, 2011, 20(4):691-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/21406334/pubmed\" target=\"_blank\" id=\"21406334\">21406334</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grosso S, Coppola G, Cusmai R, et al. Efficacy and tolerability of add-on lacosamide in children with Lennox-Gastaut syndrome. <i>Acta Neurol Scand</i>. 2014a;129(6):420-424.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/24479878/pubmed\" target=\"_blank\" id=\"24479878\">24479878</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grosso S, Parisi P, Spalice A, Verrotti A, Balestri P. Efficacy and safety of lacosamide in infants and young children with refractory focal epilepsy. <i>Eur J Paediatr Neurol</i>. 2014b;18(1):55-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/24129195 /pubmed\" target=\"_blank\" id=\"24129195 \">24129195 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grosso S, Zamponi N, Bartocci A, et al. Lacosamide in children with refractory status epilepticus. A multicenter Italian experience. <i>Eur J Paediatr Neurol</i>. 2014c;18(5):604-608.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/24836405 /pubmed\" target=\"_blank\" id=\"24836405 \">24836405 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guilhoto LM, Loddenkemper T, Gooty VD, et al, &quot;Experience With Lacosamide in a Series of Children With Drug-Resistant Focal Epilepsy,&quot; <i>Pediatr Neurol</i>, 2011, 44(6):414-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/21555051/pubmed\" target=\"_blank\" id=\"21555051\">21555051</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harden CL, Meador KJ, Pennell PB, et al. Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. <i>Neurology</i>. 2009;73(2):133-141.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/19398681 /pubmed\" target=\"_blank\" id=\"19398681 \">19398681 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heyman E, Lahat E, Levin N, Berkovitch M, Gandelman-Marton R. Preliminary efficacy and safety of lacosamide in children with refractory epilepsy. <i>Eur J Paediatr Neurol</i>. 2012;16(1):15-19.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/21924653 /pubmed\" target=\"_blank\" id=\"21924653 \">21924653 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoeltzenbein M, Supcun-Ritzler S, Langthaler M, et al &quot;Lacosamide During pregnancy: Experience of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy,&quot; <i>Reprod Toxicol</i>, 2011, 31(2):259.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kim JS, Kim H, Lim BC, et al. Lacosamide as an adjunctive therapy in pediatric patients with refractory focal epilepsy. <i>Brain Dev</i>. 2014;36(6):510-515.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/23948372 /pubmed\" target=\"_blank\" id=\"23948372 \">23948372 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rastogi RG1 Ng YT. Lacosamide in refractory mixed pediatric epilepsy: a prospective add-on study. <i>J Child Neurol</i>. 2012;27(4):492-495.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/22467791/pubmed\" target=\"_blank\" id=\"22467791\">22467791</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shiloh-Malawsky Y, Fan Z, Greenwood R, et al, &quot;Successful Treatment of Childhood Prolonged Refractory Status Epilepticus With Lacosamide,&quot; <i>Seizure</i>, 2011, 20(7):586-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/21474342/pubmed\" target=\"_blank\" id=\"21474342\">21474342</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Verrotti A, Loiacono G, Pizzolorusso A, et al. Lacosamide in pediatric and adult patients: comparison of efficacy and safety. <i>Seizure</i>. 2013;22(3):210-216.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/23298605 /pubmed\" target=\"_blank\" id=\"23298605 \">23298605 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vimpat (lacosamide) [prescribing information]. Smyrna, GA: UCB, Inc; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yorns WR Jr, Khurana DS, Carvalho KS, Hardison HH, Legido A, Valencia I. Efficacy of lacosamide as adjunctive therapy in children with refractory epilepsy. <i>J Child Neurol</i>. 2014;29(1):23-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/23143718 /pubmed\" target=\"_blank\" id=\"23143718 \">23143718 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lacosamide-pediatric-drug-information/abstract-text/17555487 /pubmed\" target=\"_blank\" id=\"17555487 \">17555487 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 83877 Version 91.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F6786825\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F11508103\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F9406528\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F9406539\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F6790656\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F6790309\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F9590984\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874836\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F9406540\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F6790525\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F9406529\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F6790305\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F6790444\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F6790319\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F6790403\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26021848\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299564\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6802892\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6790315\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F9406541\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F6790564\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F6790566\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16321857\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961941\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/83877|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=lacosamide-drug-information\" class=\"drug drug_general\">Lacosamide: Drug information</a></li><li><a href=\"topic.htm?path=lacosamide-patient-drug-information\" class=\"drug drug_patient\">Lacosamide: Patient drug information \t</a></li></ul></div></div>","javascript":null}